Literature DB >> 26396921

Mutations of the human interferon alpha-2b (hIFNα-2b) gene in cancer patients receiving radiotherapy.

Saman Shahid1, Muhammad Nawaz Chaudhry2, Nasir Mahmood3.   

Abstract

This research aimed to find out the impact of ionizing radiations on the hIFNα-2b gene of radiotherapy treated cancer patients. The gene hIFNα-2b synthesizes a protein which is an important anticancerous and antiviral protein. The cancer patients (breast, lung, thyroid, oral and prostate) who were undergoing a radiotherapy treatment were selected. A molecular analysis was performed for DNA isolation and gene amplification through PCR, to identify gene mutations. Further, by bioinformatics tools we concluded that how mutations identified in gene sequences have led to the alterations in the hINFα-2b protein in radiotherapy receiving cancer patients. The 32% mutations in the hINFα-2b gene were identified and all were frameshift mutations. Radiotherapy can impact the immune system and cancer patients may modulate their immunity. Understaning the mechanisms of radiotherapy-elicited immune response may be helpful in the development of those therapeutic interventions that can enhance the efficacy of radiotherapy.

Entities:  

Keywords:  Interferon (IFN); immunity; ionizing radiations; mutations; radiotherapy

Year:  2015        PMID: 26396921      PMCID: PMC4568781     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  60 in total

1.  A hematopoietic stromal lesion associated with fractionated radiotherapy (FxRT): time- and dose-effects.

Authors:  C J Kovacs; M J Evans; B M Daly
Journal:  Anticancer Res       Date:  2005 Jul-Aug       Impact factor: 2.480

2.  The cancer burden in the United Kingdom in 2007 due to radiotherapy.

Authors:  Jacob Maddams; D Maxwell Parkin; Sarah C Darby
Journal:  Int J Cancer       Date:  2011-08-09       Impact factor: 7.396

Review 3.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

4.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

5.  Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?

Authors:  Muhammad Hammad Aziz; Frank Schneider; Sven Clausen; Elena Blank; Carsten Herskind; Muhammad Afzal; Frederik Wenz
Journal:  Radiat Oncol       Date:  2011-12-16       Impact factor: 3.481

Review 6.  Second primary cancers after radiation for prostate cancer: a review of data from planning studies.

Authors:  Louise Murray; Ann Henry; Peter Hoskin; Frank-Andre Siebert; Jack Venselaar
Journal:  Radiat Oncol       Date:  2013-07-08       Impact factor: 3.481

7.  Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.

Authors:  Claire Vanpouille-Box; François Hindré
Journal:  Front Oncol       Date:  2012-10-10       Impact factor: 6.244

Review 8.  Human interferon alpha-2b: a therapeutic protein for cancer treatment.

Authors:  Ratih Asmana Ningrum
Journal:  Scientifica (Cairo)       Date:  2014-03-10

9.  Biological complexities in radiation carcinogenesis and cancer radiotherapy: impact of new biological paradigms.

Authors:  Hossein Mozdarani
Journal:  Genes (Basel)       Date:  2012-01-20       Impact factor: 4.096

10.  The intensity of radiotherapy-elicited immune response is associated with esophageal cancer clearance.

Authors:  Jin-lu Ma; Long Jin; Yao-Dong Li; Chen-chen He; Xi-jing Guo; Rui Liu; Yun-Yi Yang; Su-xia Han
Journal:  J Immunol Res       Date:  2014-05-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.